title: Younger patients with primary Sjögren's syndrome are more likely to have salivary IgG anti-muscarinic acetylcholine receptor type 3 antibodies.
abstract: Acetylcholine type 3 receptor (M3R) is recognized as an autoantigen in primary Sjögren's syndrome (pSS). Assay of anti-M3R antibody levels in serum is fraught with low sensitivity for diagnosis of pSS. Salivary assay is more likely to improve the diagnostic accuracy. Patients with pSS classified either by the American European Consensus Group (AECG) or American college of Rheumatology (ACR) criteria, attending rheumatology clinic between October 2014 and July 2015 were included. Hospital staff and lupus patients constituted healthy and disease controls, respectively. Evaluation of pSS included clinical evaluation, laboratory tests, ESSDAI and ESSPRI scoring. Unstimulated saliva was collected by the spitting method. Salivary IgG antibody against M3R (anti-M3R) was quantified by indirect ELISA. In this study, 43 patients with pSS, 34 with lupus and 42 healthy controls were recruited. The frequency of anti-M3R antibody levels was 55.81, 17.64 and 7 % for pSS, lupus and healthy controls, respectively. Area under the Receiver Operator Characteristic was 0.7791 (95 % CI,, 0.67-0.87). Sensitivity and specificity of the assay for diagnosis of pSS were 44.19 and 88.16 %, respectively. Salivary anti-M3R IgG antibody positivity was associated with lower age, shorter disease duration and higher globulin levels in our cohort. Salivary anti-M3R IgG antibody assay has high specificity in pSS; younger patients and those with hyperglobulinemia more frequently tested positive for this antibody.
authors.affiliation: Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, Tamil Nadu, India.
authors.forename: K
authors.initials: K
authors.lastname: Jayakanthan
authors.affiliation: Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, Tamil Nadu, India.
authors.forename: J
authors.initials: J
authors.lastname: Ramya
authors.affiliation: Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, Tamil Nadu, India.
authors.forename: Santosh Kumar
authors.initials: SK
authors.lastname: Mandal
authors.affiliation: Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, Tamil Nadu, India. drsandhya.p123@gmail.com.
authors.forename: P
authors.initials: P
authors.lastname: Sandhya
authors.affiliation: Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.
authors.forename: M
authors.initials: M
authors.lastname: Gowri
authors.affiliation: Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, Tamil Nadu, India.
authors.forename: Debashish
authors.initials: D
authors.lastname: Danda
mesh_terms: D000328:Adult; D000367:Age Factors; D001323:Autoantibodies / Q000032:analysis*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D008297:Male; D008875:Middle Aged; D043587:Receptor, Muscarinic M3 / Q000276:immunology*; D012463:Saliva / Q000737:chemistry*; D012859:Sjogren's Syndrome / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D043587:Receptor, Muscarinic M3
keywords: Acetylcholine type 3 receptor (M3R) antibody; India; Saliva; Sjögren’s syndrome
references.citation: Ann Rheum Dis. 2011 Jan;70(1):235-6
references.pmid: 20498204
references.citation: Beijing Da Xue Xue Bao. 2009 Jun 18;41(3):324-7
references.pmid: 19727217
references.citation: Rheumatology (Oxford). 2005 Feb;44(2):235-40
references.pmid: 15509625
references.citation: Clin Exp Rheumatol. 2012 May-Jun;30(3):322-6
references.pmid: 22510450
references.citation: Scand J Immunol. 2004 Mar;59(3):261-6
references.pmid: 15030576
references.citation: Ann Rheum Dis. 2002 Jun;61(6):554-8
references.pmid: 12006334
references.citation: Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87
references.pmid: 22563590
references.citation: Clin Exp Immunol. 2010 Oct;162(1):53-61
references.pmid: 20731676
references.citation: Rheumatology (Oxford). 2005 Aug;44(8):1021-5
references.pmid: 15888503
references.citation: PLoS One. 2015 Jan 28;10(1):e0116744
references.pmid: 25629973
references.citation: Clin Exp Immunol. 2001 Jun;124(3):480-5
references.pmid: 11472412
references.citation: Rheumatology (Oxford). 2011 May;50(5):879-84
references.pmid: 21217140
references.citation: Ann Rheum Dis. 2008 Jan;67(1):136-7
references.pmid: 18077545
references.citation: Medicine (Baltimore). 2008 Jul;87(4):210-9
references.pmid: 18626304
references.citation: J Autoimmun. 2012 Aug;39(1-2):15-26
references.pmid: 22575069
references.citation: Scand J Immunol. 1999 Jan;49(1):7-10
references.pmid: 10023850
references.citation: Open Rheumatol J. 2015 Jun 26;9:36-45
references.pmid: 26161156
references.citation: J Clin Pathol. 1968 Sep;21(5):656-60
references.pmid: 5697370
references.citation: Arthritis Care Res (Hoboken). 2013 Aug;65(8):1358-64
references.pmid: 23436737
references.citation: J Clin Immunol. 2011 Oct;31(5):840-7
references.pmid: 21744183
references.citation: Chin Med J (Engl). 2010 Nov;123(22):3252-7
references.pmid: 21163125
references.citation: Clin Exp Immunol. 1996 Jun;104(3):454-9
references.pmid: 9099930